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Objective: To review the options for acute and maintenance pharmacological treatment of bipolar
disorder in children and adolescents, including the treatment of bipolar depression and comorbid
attention deficit/hyperactivity disorder (ADHD).
Methods: Narrative review of randomized clinical trials and open-label studies published from 2000 to
2012. The PubMed and PsycINFO websites were queried. Case series were included when a higher
level of evidence was not available.
Results: Published data from randomized controlled trials (RCTs) in acute mania/hypomania with
significant responses are available for lithium, topiramate, risperidone, olanzapine, and aripiprazole.
Open trials of lithium and lamotrigine show that these drugs may be effective in the treatment of
depressive episodes. No trials of selective serotonin reuptake inhibitors (SSRIs) have been
conducted. In the treatment of comorbid ADHD, there are encouraging findings with mixed
amphetamine salts and atomoxetine; conflicting results are observed with methylphenidate.
Conclusions: Published RCTs of traditional mood stabilizers are scarce, but the best available
evidence (results from meta-analytic regression) suggests that second-generation antipsychotics
(SGAs) as a group are more effective in reducing manic symptoms. Risperidone was the only one
included in head-to-head comparisons (vs. lithium and divalproex), showing superiority in terms of
efficacy, but with more metabolic side effects, which were also more common in most of the SGAs.
There are few studies addressing the treatment of ADHD and depression. Brazilian guidelines for the
treatment of pediatric bipolar disorder should also include some SGAs (especially risperidone and
aripiprazole) as first-line treatment, and these drugs should be provided by the public health services.
Keywords: Pediatric bipolar disorder; pharmacotherapy; treatment; lithium; anticonvulsants;
atypical antipsychotics
Introduction
Pediatric bipolar disorder (PBD) is a chronic and disabling
condition that leads to serious disturbances in the lives of
patients and their families.1 Affected children and
adolescents have significantly higher rates of morbidity
and mortality compared with healthy children. The
impairment in social, family, and academic functioning
lead to reduced quality of life.2,3 In addition, increased
rates of suicidal ideation and suicidal behavior are
observed.4 Current data suggest the prevalence of PBD
is around 0.1-1%.5
In contrast to the robust evidence for pharmacotherapy
in adults with bipolar disorder (BD), uncertainties remain
regarding the treatment of PBD.6 As will be seen
throughout the text, most recent studies have not
addressed the classic antimanic agents, but evidence of
the efficacy of atypical antipsychotics is mounting.
However, these drugs have also been associated with
significant adverse effects, especially weight gain, loss of
glycemic control, dyslipidemia, and hyperprolactinemia,
making the choice of drug to be used often difficult.7
Another aspect that should be taken into account is the
high rate of comorbidity with other psychiatric disorders,
especially with attention deficit/hyperactivity disorder
(ADHD), which is present in more than 40% of patients
with PBD in clinical samples and in about 10-15% of
children and adolescents in community samples.8,9 In a
2003 study conducted at Hospital de Clı´nicas de Porto
Alegre (HCPA), a tertiary care center in Southern Brazil,
the rate of comorbid ADHD in patients with PBD was
58.3%.8 Earlier studies have found ADHD rates of 93% in
children with BD, 88% in adolescents who had childhood-
onset mania, and 59% in adolescents who had adoles-
cent-onset BD.10 Comorbidity with ADHD is associated
with worse functional outcomes and even worse
responses to treatment.11,12
In view of these issues, the present study sought to
review the state of the evidence for pharmacological
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treatment of BD in children and adolescents, including the
treatment of comorbid PBD/ADHD.
Methods
This narrative review was conducted by searching
the PubMed and PsycINFO websites for the following
keywords, individually and two by two: bipolar disorder,
adolescent, child, pediatric, juvenile, early-onset, mania,
treatment, pharmacotherapy, lithium, valproate, dival-
proex, carbamazepine, oxcarbazepine, topiramate,
lamotrigine, gabapentin, atypical antipsychotics, risper-
idone, paliperidone, olanzapine, quetiapine, ziprasidone,
aripiprazole, combined therapy, and augmentation. Two
reviewers (TLP and CPZ) conducted the search inde-
pendently. When any discrepancies were detected,
results were combined. We also assessed the references
of other literature reviews. The study included review
articles, meta-analyses, randomized clinical trials, and
open trials published between 2000 and 2012 in
Portuguese, Spanish, and English. Unpublished studies
available from other sources, such as the FDA website or
symposia annals, were also included. Unpublished data
did not undergo peer-review and this should be con-
sidered a possible limitation for these studies. Case
series and case reports were not included when higher-
level evidence was available. References for case
series and case reports are available from the authors
on request.
Results
The studies found in the review were divided as follows:
1) treatment of mania/hypomania; 2) treatment of bipolar
depression; 3) maintenance treatment; and 4) treatment
of comorbid ADHD. Within these divisions, they were
categorized according to the strength of scientific
evidence in the area: a) randomized controlled trials
(RCTs) and meta-analyses; b) open, retrospective, or
follow-up studies.
Treatment of mania/hypomania/mixed states
Randomized controlled trials/meta-analyses
At the time of this review, our search strategy yielded 15
RCTs13-27 and two meta-analyses.28,29
Geller et al. conducted the first RCT in PBD.13
Adolescents with BD I or II or major depressive disorder
and supposed predictors of bipolarity (delusions, switch-
ing to mania during tricyclic antidepressant treatment,
marked psychomotor retardation, and BD in a first-degree
relative) with comorbid substance use disorder were
assessed in a 6-week randomized, double-blind, placebo-
controlled trial (DBPCT) using lithium (0.9-1.3 mEq/L)
(n=25; age, 16.361.2 years). The authors found that
lithium was more effective than placebo in improving
functioning scores according to the Children Global
Assessment Scale (CGAS). Also, the analysis of urine
drug assays was significantly different for the lithium
(n=13) vs. the placebo (n=12) groups, but there was no
between-group difference in measures of mood symp-
toms according to the Schedule for Affective Disorders
and Schizophrenia for School-Aged Children (K-SADS)
mood items. There were limitations in the study due to the
fact that the diagnosis of BD was made in a flexible way,
allowing entry of patients with clinical depression and
predictors of future bipolarity into the protocol. Polyuria
was the most frequent adverse effect.
Kowatch et al. conducted an 8-week RCT of dival-
proex, lithium, or placebo (unpublished, presented at an
AACAP meeting) in 153 subjects aged 7 to 17 years with
BD I in manic or mixed episode.14 Response was defined
as Clinical Global Impressions-Improvement scores of 1
or 2 (very much or much improved). Response rates
were: 54% for divalproex; 42% for lithium; and 29% for
placebo. Lithium showed a trend toward efficacy but did
not clearly separate from placebo. Effect sizes for lithium
and divalproex were moderate.
Wagner et al. evaluated the efficacy of divalproex
extended-release (ER) as monotherapy for PBD during a
DBPCT in 150 patients (manic or mixed episode, aged
10-17 years).15 Divalproex was given to a maximum
dosage of 35 mg/kg/day (serum levels: 80 to 125 mg/mL)
during 4 weeks. Concomitant use of antipsychotics,
antidepressants, or other mood stabilizers was not
allowed. Participants were assessed with the Young
Mania Rating Scale (YMRS), the Clinical Global
Impression – Severity scale (CGI-S), the Clinical Global
Impression – Improvement scale (CGI-I), and the
Children’s Depression Rating Scale – Revised (CDRS-
R). There was no significant difference between the
placebo and divalproex ER groups in YMRS total score
(-8.8 vs. -7.9 respectively, p = 0.604) or in secondary
measures. Divalproex was similar to placebo in the
incidence of adverse effects, except for weight gain,
which was higher in the divalproex ER group. The most
common adverse events were headache and vomiting.
A 6-week double-blind, randomized trial of risperidone
(0.25-2 mg/day) plus placebo vs. divalproex (60-120 mg/mL)
plus placebo was conducted by Pavuluri et al. in 66
patients aged 8-18 years.16 Reduction in YMRS scores
was the primary efficacy measure. The secondary
measures were the CDRS-R, the CGI-BP, the Overt
Aggression Scale (OAS), and the Brief Psychiatric Rating
Scale for Children (BPRS-C). Response rates were
defined as o 50% improvement in YMRS for mania and
o 50% improvement in CDRS-R for depression. The rates
achieved for manic symptoms were 78.1% for risperidone
vs. 45.5% for divalproex (p , 0.01); and for depressive
symptoms, 65.6% for risperidone vs. 42.4% for divalproex
(p , 0.1). The remission rates (YMRSf 12 and CDRS-D
f 28) were 62.5% with risperidone vs. 33.3% with
divalproex (p , 0.05). There were no significant differ-
ences in weight gain. The dropout rate was 24% in the
risperidone group vs. 48% in the divalproex group, mostly
due to increased irritability.
Another divalproex DBPCT was conducted in 30
adolescents (age 12-18 years) with bipolar I manic or
mixed episode by DelBello et al.17 Patients received an
initial dose of divalproex, 20 mg/kg, and were then
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randomized to receive adjunctive quetiapine (maximum
dose of 450 mg/day) or placebo, for 6 weeks. The
primary efficacy measure was change in YMRS scores.
The quetiapine group demonstrated a greater reduction
in YMRS scores compared with the placebo group
(p = 0.03). In addition, the YMRS response rate was
significantly higher the in divalproex + quetiapine group
than in the placebo + divalproex group (87 vs. 53%,
p = 0.05). Sedation was the main adverse effect, and was
significantly more common in the quetiapine group.
A DBPCT investigated the use of oxcarbazepine
monotherapy in 116 youths with BD in manic or mixed
episode.18 The patients were allocated to receive flexible
doses of oxcarbazepine (maximum dose 900-2,400 mg/day)
or placebo for 7 weeks. The primary efficacy measure
was the mean change from baseline to endpoint in the
YMRS. Oxcarbazepine monotherapy (mean dose 1,515
mg/day) did not significantly improve YMRS scores at
endpoint compared to placebo. The oxcarbazepine group
reported the occurrence of dizziness, nausea, somno-
lence, diplopia, fatigue, and rash with an incidence at least
twice that of the placebo group.
A pilot DBPCT with 56 children and adolescents (age
6-17 years) with a diagnosis of bipolar I disorder receiving
topiramate (n=29) or placebo (n=27) was conducted to
analyze the efficacy of topiramate monotherapy for acute
mania in children and adolescents.19 Efficacy measures
included the YMRS, BPRS-C, CDRS, the CGAS, and the
CGI-I. However, the study was discontinued prematurely
when trials on the use of topiramate in adults with mania
showed no efficacy. In the short period in which the study
was conducted, the only statistically significant differ-
ences observed were in variation in the YMRS (p = 0.003)
and BPRS-C (p = 0.048). Adverse events of topiramate
included decreased appetite, nausea, diarrhea, and
paresthesia.
A DBPCT including 169 children and adolescents (age
10-17 years) diagnosed with bipolar I disorder, experien-
cing a manic or mixed episode, in which participants were
randomized to receive placebo (n=50), risperidone 0.5-
2.5 mg/day (n=61), or risperidone 3-6 mg/day (n=58) for 3
weeks was conducted by Haas et al.20 Subjects were
assessed using the YMRS, the CGI-I, the Clinical Global
Impression–Bipolar (CGI-BP) scale, and the BPRS-C.
Significant improvement in the YMRS score was
observed in both risperidone groups as compared with
placebo (p , 0.001). Twenty-six percent of subjects
receiving placebo achieved a clinical response, com-
pared with 59% in the 0.5-2.5 mg risperidone group (p =
0.002) and 63% in the 3-6 mg risperidone group (p ,
0.001). The adverse events most commonly associated
with risperidone were somnolence, headache, and
fatigue (dose-dependent increase in percentage), as well
as moderate weight gain. The study results suggest that
the lower dose range is associated with a better safety
profile.
An 8-week RCT was conducted by Geller et al. with
279 children and adolescents aged 6 to 15 years.21
Subjects were randomly assigned to receive risperidone
(4-6 mg), lithium (1.1-1.3 mEq/L), or divalproex sodium
(111-125 mg/mL). The primary outcome measure was the
Children Global Impressions for Bipolar Illness
Improvement–Mania (CGI-BP-IM). Patients were also
assessed with the Modified Side Effects Form for
Children and Adolescents and the K-SADS – Mania
Rating Scale (KMRS). Patients in the risperidone group
had a significantly higher response rate than those
treated with lithium (68.5 vs. 35.6%; p , 0.001) or those
treated with divalproex sodium (68.5 vs. 24.0%; p ,
0.001). There was no significant difference in response
rates between the lithium and the divalproex groups.
Mean weight gain was significantly greater with risper-
idone than lithium (3.31 vs. 1.42 kg; p , 0.001) and
divalproex sodium (3.31 vs. 1.67 kg; p , 0.001). Greater
increases in body mass index and prolactin levels were
detected in subjects treated with risperidone.
A 3-week multicenter DBPCT was conducted by Tohen
et al. with 161 adolescents aged 13-17 years with an
acute manic or mixed episode.22,30 Subjects received
either olanzapine at flexible doses (2.5-20 mg/day
[n=107]) or placebo (n=54). There was a significantly
greater reduction in the YMRS scores of patients
receiving olanzapine than in the placebo group (-17.65
vs. -9.99; p f 0.001). The mean weight change was
significantly greater for patients receiving olanzapine
relative to patients receiving placebo (3.7 vs. 0.3 kg; p
f 0.001), as was the frequency of other side effects,
such as drowsiness and sedation. Furthermore, in the
olanzapine group, significant increases in systolic blood
pressure (p = 0.001), fasting glucose (p , 0.002), total
cholesterol (p , 0.001), serum prolactin levels (p ,
0.001), and liver enzymes (AST, p , 0.002; ALT, p ,
0.003) were reported.
The effectiveness of quetiapine in the treatment of
acute manic episodes associated with BD in children and
adolescents aged 10 to 17 years was demonstrated in a
3-week DBPCT.23,31 Patients were randomized to receive
quetiapine 400 mg/day (n=95), quetiapine 600 mg/day
(n=98), or placebo (n=91). Quetiapine 400 mg/day and
600 mg/day were statistically superior to placebo,
according to changes in YMRS scores (p , 0.001 for
both doses vs. placebo). Improved functioning according
to the CGAS scores was also observed.
A 4-week DBPCT was designed by DelBello et al. to
evaluate the efficacy of ziprasidone compared to placebo
in 238 children and adolescents aged 10-17 years with
BD-I.24,28 The target dose was 80-160 mg/day for
subjects weighing . 45 kg and 40-80 mg/day for children
weighing , 45 kg. The primary efficacy measure was the
change in YMRS total score. A reduction. 50% in YMRS
was achieved in 62% of the subjects in the ziprasidone
group, compared to 35% of the subjects in the placebo
group (p , 0.001). Difference from placebo was only
achieved at week 4. Patients receiving ziprasidone 40-80
mg/day showed less improvement than the group
receiving 80-160 mg/day, but it was unclear whether this
difference was due to the dose or to a weight effect, since
the dosing mechanism is related to patient weight. The
most frequent side effects among patients treated with
ziprasidone were dystonia, headache, and sedation.
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Aripiprazole demonstrated statistically significant
superiority over placebo in the treatment of acute mania
or mixed states in a 4-week DBPCT (n=296).22,25
Patients were randomized to receive aripiprazole 10
mg, aripiprazole 30 mg, or placebo during a 4-week acute
phase and then continued the allocated treatment for over
26 weeks. A reduction of at least 50% in YMRS total
score at week 4 was achieved by 44.8%, 63.6%, and
26.1% of subjects in the aripiprazole 10 mg, aripiprazole
30 mg, and placebo groups respectively (p , 0.01 for
both doses vs. placebo). Adverse events were mild to
moderate for the two aripiprazole subgroups, with
somnolence, parkinsonism, and akathisia being most
frequent.
A DBPCT conducted at the HCPA Department of Child
and Adolescent Psychiatry (n=43, 8-17 years) included
patients with BD in manic/mixed episode comorbid
with ADHD.26 Patients were randomized to receive
placebo or aripiprazole monotherapy to the maximum
dose of 20 mg/day for 6 weeks. The aripiprazole group
had a greater reduction in outcome parameters (YMRS,
Children Mania Rating Scale – Parent version [CMRS-P]
and CGI-S), higher rates of response and remission, and
a significant reduction in ADHD symptoms despite no use
of concomitant stimulant medication. The most common
adverse events reported by the aripiprazole group were
somnolence and drooling.
Regarding alternative treatments, a 16-week DBPCT of
flax oil was conducted on 51 subjects with BD aged 6-17
years.32,27 Patients had a previous failure in symptom
stabilization and/or were intolerant to lithium and/or
valproate and/or atypical antipsychotic therapy, or
desired participation in a study without conventional
treatment. The oil contained the omega-3 fatty acid a-
linolenic acid (a-LNA). Patients were randomly assigned
to receive supplementation with flax oil, containing 550
mg a-LNA/g (maximum dosage: 12 capsules/day) or an
olive oil placebo adjunctively or as monotherapy. No
difference between flax oil or placebo was detected in the
measures of mood symptoms and global functioning
(YMRS, CDRS-R, and CGI-BP).
No DBPCTs of carbamazepine, lamotrigine, gabapen-
tin, paliperidone, or clozapine were identified by our
literature review. A summary is presented in Table 1.
Biederman et al. conducted a meta-analysis compar-
ing open-label studies and randomized placebo-
controlled trials (RPCTs) to evaluate the accuracy of
information provided by open-label studies as predictors
of the findings of RPCTs.28 Fourteen studies were
included (19 observations: 11 open-label trials and 8
RPCTs) of second-generation antipsychotics (SGAs)
and mood stabilizers. Similarities between the effects
of treatment reported in open-label studies and
RPCTs were found, suggesting that open studies may
predict treatment safety and efficacy. Furthermore, a
higher YMRS result difference was found for risperidone
in RPCTs than in open-label studies. There were
no other significant differences between open-label
studies and RPCTs with other individual medications
evaluation.
Liu et al. conducted a systematic review of the
available literature on the effectiveness of agents for the
treatment of mania, depression, and ADHD in children
and adolescents.29 The review included 29 open-label
studies and 17 RPCTs covering 2,666 individuals and
evaluated mood stabilizers, SGAs, and naturopathic
compounds (flax oil and omega-3). Modest effects were
reported for traditional antimanic agents, such as lithium
carbonate, divalproex sodium, and carbamazepine, when
used as monotherapy. The SGAs as a group were
significantly more effective than mood stabilizers and
naturopathic compounds on meta-analytic regression of
RCTs. No significant difference was observed between
risperidone, olanzapine, quetiapine, ziprasidone, and
aripiprazole (for which RPCTs are available). However,
SGAs were also associated with increased rates of
weight gain and somnolence.
A review of the available literature shows that
risperidone, olanzapine, quetiapine, ziprasidone, and
aripiprazole have a large effect in reducing YMRS scores.
RPCTs of traditional mood stabilizers are scarce, but the
best available evidence (results from meta-analytic
regression) suggests SGAs are more effective in redu-
cing manic symptoms. Correll et al. conducted a
comparative analysis of RPCTs of SGAs and mood
stabilizers.39 Nine RPCTs enrolling young patients were
found (five evaluating SGAs and four about mood
stabilizers). The results of the study show that SGAs
may be more effective in reducing manic symptoms than
mood stabilizers. Head-to-head comparisons are also
scarce. The two available studies suggest risperidone is
more effective than lithium and divalproex, but more
metabolic adverse events were associated with risper-
idone use. In these studies, divalproex seemed to be
more effective than lithium.
Open-label studies
Our search strategy yielded 20 open-label, retrospective,
or follow-up studies available in the literature at the time
the review was concluded. Data are summarized in Table
2.40-59 Case reports and case series were detected, but
were not included in the text due to the availability of
higher-level evidence for the psychopharmacological
agents of interest. Nevertheless, we recommend analysis
of these case series and reports, which are available from
the authors on request.
Kowatch et al. conducted an open-label study of
lithium, divalproex sodium, or carbamazepine (n=42) for
6 weeks.58 All three drugs were found effective. There
were no significant differences between the three drugs.
In an open trial of carbamazepine (7886252 mg daily,
n=27, 8 weeks), 16 (59%) children completed the study,
and treatment with carbamazepine was associated with
statistically significant, though modest, levels of improve-
ment in mean YMRS scores (10.1610.2, p , 0.001),
suggesting lack of complete resolution of mania.59
Biederman et al. conducted a 12-week, open-label,
prospective trial with 39 subjects (age 6-17 years) using
lamotrigine monotherapy at doses ranging from
160.76128.3 mg/day in subjects , 12 years (n=22) to
TL Peruzzolo et al.396
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219.16172.2 mg/day in children 12-17 years old
(n=17).44 Patients were assessed with the YMRS, the
CGI-I, CDRS, and BPRS. The response rates, defined as
a reduction in YMRS scores o 30% or improvement of
mania on CGI-I (f 2), was 66%; 54% of the subjects had
a reduction in YMRS scores o 50% (p ,0.001).
Lamotrigine was also associated with improvement in
depressive, ADHD, and psychotic symptoms, but 25% of
the patients discontinued the trial due to adverse events,
dermatologic side effects being the most common.
In open trials of combination treatment, risperidone as
an augmentation agent in patients exhibiting poor
response to lithium (n=38) was effective and well
tolerated, with response rates of 85.7% (defined as a
decrease in the YMRSo 50%).51 Divalproex sodium plus
risperidone or lithium plus risperidone in 37 patients
promoted significant improvement in the YMRS, the
CDRS-R, and the CGI-BP (p , 0.001). There were no
significant between-group differences in terms of efficacy,
safety, or tolerability.52
Wozniak et al. conducted an open trial evaluating 40
patients aged 6 to 17 years, comparing olanzapine
monotherapy with the combination of olanzapine plus
topiramate.54 The topiramate group presented a reduced
weight gain, but the combination was not superior to
olanzapine monotherapy in reducing manic symptoms.
Biederman et al. evaluated the use of olanzapine
(6.362.3 mg/day) or risperidone (1.460.5 mg/day)
monotherapy in 31 preschoolers (age 4-6 years) in an
8-week open trial.53 The primary efficacy measures were
a reductiono 30% in the YMRS and improvement in the
CGI scale. Both antipsychotics proved to be effective in
reducing manic symptoms. There was no difference in
response rate between risperidone and olanzapine (69%
vs. 53%, p = 0.4). Weight gain was observed with the two
drugs. Significantly higher prolactin serum levels were
observed with risperidone.
Masi et al. assessed the effect of clozapine in 10
subjects (age 12 to 17 years).55 Improvements measured
with CGI-I, YMRS, BPRS, CGA, and CGAS were
significant (p , 0.001). The average clozapine dose
was 75-300 mg/day. The most common side effects were
increased appetite, sedation, enuresis, and sialorrhea.
There was a 10.7% mean increase in body weight.
Rucklidge et al. researched the effect of the intake of a
micronutrient formula, composed essentially of vitamins
and minerals (EMPower), for 3-6 months in 120 subjects
aged 7-18 years with BD.57 Around 80% of these patients
were on psychiatric medication and 24% reported
comorbidity with ADHD. The data were obtained from
the formula manufacturer’s database. Clients were asked
to complete a daily symptom checklist based on the
DSM-IV and send it to the company over the internet, fax,
or phone. About 46% of patients experienced . 50%
improvement in BD symptoms, but 38% of the sample
continued to require psychotropic medication.
Open-label studies evaluating treatment options for
mania exhibit similar results to those found in RCTs. The
SGAs are effective in reducing effect measures, as do
most mood stabilizers, with the exceptions of topiramate
and carbamazepine. Open-label studies of alternative
treatments exhibited modest results.
Treatment of bipolar depression
Randomized controlled trials/meta-analyses
At the time of this review, only one RCT about treatment
of bipolar depression had been published. DelBello and
colleagues conducted a DBPCT of quetiapine in 32
subjects (age 12-18 years) with BD in a current
depressive episode.33 Subjects underwent a 300-600
mg trial of quetiapine or placebo for 8 weeks. Treatment
response was defined as a reduction in CDRS-Ro 50%.
There was no statistically significant difference between
the placebo and quetiapine groups in changes in CDRS-
R scores from baseline to endpoint (p = 0.89), response
rates (placebo = 67% vs. quetiapine = 71%), or change in
secondary efficacy measures. The most frequent side
effect of quetiapine was dizziness.
Open-label studies
Our search strategy yielded three open-label studies.60-62
A 6-week open-label study of 27 adolescents aged 12 to
18 years with bipolar I disorder experiencing an acute
depressive episode was conducted by Patel et al. to
examine the effectiveness of lithium in decreasing
depressive symptoms.60 The subjects received lithium
30 mg/kg, which was adjusted to achieve a therapeutic
serum level of 1.0-1.2 mEq/L. Response rates, defined as
a reduction in CDRS-R scoreo 50%, occurred in 48% of
the subjects. Thirty percent of the patients achieved
remission (CDRS-R score f 28 and a CGI-BP
Improvement score of 1 or 2) with lithium monotherapy.
The most common side effects were headache (74%),
nausea/vomiting (67%), stomachache (30%), and
abdominal cramps (19%).
An 8-week open-label trial of lamotrigine was con-
ducted by Chang et al. with 20 adolescents (ages 12-17
years) with BD experiencing a depressive episode, using
lamotrigine as monotherapy or with other mood stabilizer
and/or stimulant drug (if ADHD was diagnosed).61 The
primary measures of response were improvement on the
CGI at week 8 and a decrease of at least 50% in the
CDRS-R scores; these endpoints were achieved in 84%
and 63% of the subjects, respectively. Significant
decreases in the YMRS (p = 0.001) and the Overt
Aggression Scale-Modified scores (p = 0.001) were
observed. No significant adverse effects were reported
during the trial.
A retrospective review of medical records of 59 patients
with PBD was conducted by Biederman et al., evaluating
the use of selective serotonin reuptake inhibitors (SSRIs)
and mood stabilizers in bipolar depression.62 SSRIs were
associated with significant improvement of bipolar
depression, but increased the chances of recurrence of
manic symptoms. Furthermore, the use of mood stabi-
lizers was found to improve manic symptoms, but did not
change the course of bipolar depression. SSRIs did not
modify the improvement of manic symptoms obtained
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with mood stabilizers. In conclusion, this review suggests
that treatment of bipolar depression in children and
adolescents can be performed with an SSRI, as long as
it is preceded by adequate control of manic symptoms
with mood stabilizers. Prospective studies are urgently
needed to confirm this finding.
There are few studies regarding bipolar depression in
children and adolescents, and all the available trials have
limitations, such as small sample sizes and lack of a
placebo group. Based on current studies, lithium (mono-
therapy) and lamotrigine (monotherapy or adjunctively)
seem to be effective treatments. SSRIs may be an
alternative to treat depressive symptoms, but current
studies suggest their use only when combined with
antimanic agents. Studies on this topic are urgently
needed.
Maintenance treatment
Randomized controlled trials
Our search strategy yielded three RCTs on maintenance
treatment.
As a continuation of the open-label study of lithium
carried out by Kafantaris et al., a DBPCT phase was
conducted.34 Adolescents who initially responded to
lithium were randomly assigned to lithium or placebo for
2 weeks. The results suggested that both lithium and the
placebo had similar rates of symptoms exacerbation
(52.6% for lithium; 61.9% for placebo). Despite promising
results in the open-label study phase, a large treatment
effect for lithium was not found in the maintenance phase.
Of 139 subjects aged 5-17 years who were initially
treated with lithium combined with divalproex, 60 patients
were randomly assigned to discontinue one of the agents
for 76 weeks, while the others were kept on combination
therapy.35 There was no difference in time to recurrence
of symptoms between the lithium and divalproex mono-
therapy groups. Receiving both drugs again promoted
remission rates of 89.5%.
As a continuation of an open-label study of aripiprazole
monotherapy with 96 subjects (age 4-9 years), Findling et
al. conducted a DBPCT with 60 patients from the initial
study who achieved remission and stabilization.36 These
patients were randomly assigned to receive aripiprazole
(mean dose: 6.462.1 mg/day) or placebo for 72 weeks.
The primary outcome measure for this phase of the trial
was time to discontinuation due to a mood event. The
median (6 standard error) time in weeks to discontinua-
tion was longer in the aripiprazole group (6.14611.88; p =
0.005) than with placebo (2.2960.38; p = 0.003), leading
to the conclusion that aripiprazole may be a more
effective long-term treatment than placebo. The most
common side effects with aripiprazole were stomach
pain, increased appetite, and headaches.
Open-label studies
Three open-label studies were detected.
An 8-week prospective, open-label trial was conducted
by Findling et al. in 38 patients aged 5 to 17 years with BD
I or II who remitted with combination therapy consisting of
lithium and divalproex.63 The main issue raised by the
authors was whether patients who achieved stability on
combination drug therapy would benefit from receiving
more than one drug during long-term treatment. For this
purpose, patients subsequently discontinued one of the
agents. Those who became symptomatic during main-
tenance monotherapy with lithium or divalproex pre-
sented an 89.5% remission rate when treated with the
same combination, according to the YMRS, CDRS-R,
CGAS, and CGI-S.
An 11-week open trial was conducted by Tramontina
et al. with 10 patients (age 11-17 years) who were
previously on a single mood stabilizer or antipsychotic
and presented weight gain greater than 5%.64 The
subjects were enrolled to switch to topiramate. The
main hypothesis was that topiramate monotherapy
would be able to maintain mood stabilization while
reducing body weight. There was a significant reduction
in YMRS scores (p , 0.01) as well as in body weight
(p , 0.01).
A 48-week open-label prospective study was con-
ducted by Duffy et al. with 18 patients aged 13 to 20 years
and meeting DSM-IV lifetime criteria for BD type I, II, or
NOS.65 Initially, for 8 weeks, patients received quetiapine
in increments of 50 mg daily to a maximum of 800 mg/day
according to improvement of clinical symptoms.
Simultaneously, other psychotropic drugs previously in
use were discontinued if possible. Concomitant use of
clonazepam or zopiclone for insomnia was allowed. Five
patients required combination therapy. In that trial,
quetiapine was effective and well tolerated. CGI-S scores
declined over the course of the trial (p , 0.01). The most
common side effects were somnolence and flu-like
symptoms.
Maintenance treatment is mandatory due to the high
recurrence rates in PBD. The effect of combined lithium
and divalproex sodium therapy is controversial: in an
open-label trial, it seemed effective, but this result was
not replicated in a later RCT. Topiramate showed
effectiveness in reducing YMRS scores and weight after
mood stabilization with other agents. Quetiapine has also
demonstrated a positive response. However, high-level
evidence is scarce. Most drugs were not assessed in
long-term treatment trials. Studies where even one of the
agents was discontinued revealed faster recurrence of
symptoms. The current expert recommendation is main-
tenance of the same medication and dosage with which
the patient was initially stabilized and management of
comorbidities.
Comorbid PBD/ADHD
Randomized controlled trials
Our search strategy yielded three RCTs of patients with
comorbid PBD/ADHD.
Scheffer et al. conducted a two-stage trial wherein
patients who had achieved mood stabilization
with divalproex sodium, but no significant improvement
of ADHD symptoms, were invited to join a 4-week
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randomized, crossover DBPCT of mixed amphetamine
salts (n=30, age 8-17 years).37 Significant improvement
in ADHD symptoms was observed in the MAS group,
while no significant between-group change in the
YMRS was detected. Mixed amphetamine salts were
considered safe and effective without promoting destabi-
lization of BD.
Findling et al. conducted a 4-week crossover DBPCT of
methylphenidate in 16 children and adolescents with BD/
ADHD previously on mood stabilizers, with residual
ADHD symptoms.38 Best dose week of treatment (5
mg-10 mg-15 mg) was compared to placebo and a
significant difference was observed between medicated
and non-medicated groups in the ADHD Rating Scale-IV
(ADHD-RS-IV) and Conners Parent Rating Scale. No
significant difference was observed in changes in YMRS
and CDRS-R scores.
Zeni et al.11 conducted a randomized crossover trial of
methylphenidate and placebo (2 weeks each) in children
and adolescents with BD/ADHD previously stabilized with
aripiprazole (n=16; age 8-17 years). No significant
differences between the effects of methylphenidate and
placebo were detected in ADHD (p = 0.97) or manic (p =
0.34) symptoms. Significant improvement in depressive
symptoms was observed in the methylphenidate group (p
= 0.01). One patient discontinued the trial due to the
onset of a severe mixed episode. No other significant
adverse events were observed.
Open-label studies
Twelve patients (age 6-17 years) with BD/ADHD under-
went an 8-week open trial of atomoxetine combined with
at least one mood stabilizer or antipsychotic.66 A
significant decrease in ADHD-RS-IV scores was
observed, with no significant changes in YMRS or
CDRS-R scored. Response (o 25% decrease in the
ADHD-RS-IV) was seen in eight subjects (67%) and
remission (o 40% decrease in the ADHD-RS-IV), in six
patients (50%). Two subjects discontinued early due to
worsening of mood symptoms. Placebo-controlled stu-
dies are needed to clarify the role of atomoxetine in this
population.
Treatment of comorbid BD/ADHD has been under-
studied. The current evidence suggests the addition of a
stimulant (MAS or methylphenidate) or atomoxetine after
mood stabilization. Methylphenidate does not seem to be
effective in reducing ADHD symptoms when combined
with aripiprazole. Although all agents were safe and well
tolerated and mood destabilization is the exception rather
than the rule, caution is still warranted when introducing
stimulants and/or atomoxetine to the therapeutic regimen.
Discussion
Research into the treatment of BD in children and
adolescents has increased in recent years, especially
regarding the use of SGAs. However, many uncertainties
remain. Current algorithms suggest starting with mono-
therapy and then progressing to combination treatment with
two different classes of drugs.67 Data from RPCTs of
traditional mood stabilizers are scarce. The efficacy of some
atypical antipsychotic agents (risperidone, olanzapine,
quetiapine, ziprasidone, and aripiprazole) has been well
demonstrated, especially for aripiprazole and risperidone.
Aripiprazole showed efficacy in at least two published
RCTs.25,26 Risperidone also showed higher efficacy than
divalproex sodium in two different studies.20,21 Although no
specific SGA has proved to be more effective than others,
available meta-analyses and comparative studies of
RPCTs suggest that SGAs are more effective than
traditional mood stabilizers. Furthermore, a head-to-head
comparison of risperidone vs. lithium and divalproex
showed that risperidone was superior in terms of efficacy,
but with more metabolic side effects.21 No RPCTs of
paliperidone, quetiapine, or ziprasidone have been pub-
lished to date, and there are no large studies evaluating
clozapine in children and adolescents, except for case
series. In clinical practice, clozapine is reserved for
treatment-refractory cases because of its side effect profile;
hence, investigations with greater methodological robust-
ness are required.
Often, children and adolescents with BD trial several
medications unsuccessfully before achieving proper
mood stabilization.13 A study of children and adolescents
with BD from community samples showed that patients
were treated, on average, with 3.461.5 medications and
had received approximately 6.363.7 psychotropic drugs
previously.68,69 Combination therapy is common, and
combinations of SGAs are becoming particularly more
frequent. A study by the Florida Mental Health Institute
evaluating the medical records of 12,764 children (484 of
them diagnosed with BD) and 10,419 adolescents (823 of
them diagnosed with BD) on Florida Medicaid over 5
years showed that 7% of children and 8% of adolescents
were using more than one antipsychotic drug, although
evidence indicating the efficacy of antipsychotic combina-
tions in children with BD is limited to reviews of medical
records.70,71 Some data from studies conducted in adults
suggest that the side effects of SGAs may be exacer-
bated when these drugs are used in combination.72
Based on this information, we believe that combination
antipsychotic therapy should be reserved for cases where
patients had multiple failures on several different trials of
monotherapy, including clozapine. Controlled studies on
polypharmacy of antipsychotics in PBD are needed to
determine the risk-benefit ratio of this treatment option.
Each drug should be trialed for a sufficient time and at a
sufficient dosage to determine the effectiveness of the
agent. Generally, a 6- to 8-week course of an antimanic
agent, at appropriate doses, is recommended before
adding or replacing it with another drug.5,73-75
The lack of replication of results of RPCTs and the lack
of head-to-head comparisons of different psychopharma-
cologic approaches precludes the designation of any
therapeutic option as having stronger evidence support-
ing its use in the treatment of BD in children. However, it
bears stressing that, in Brazil, the only drugs provided
through the national Unified Health System (SUS) are
lithium, carbamazepine, and valproate. The effect of
lithium has not been adequately studied in RPCTs of
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PBD. Studies of valproate suggest it is no different from
placebo, and no RPCT is available for carbamazepine.
The only comparison of these agents vs. risperidone
found that risperidone was more effective than either
lithium or valproate. Despite greater documented efficacy
(except for paliperidone and clozapine), SGAs are not
provided by the government for the treatment of BD,
being reserved for proven cases of schizophrenia. This
further limits the choice of the most suitable drugs for
treatment of pediatric patients with BD. We suggest that
risperidone and aripiprazole be included in SUS formul-
aries as a standard treatment for PBD, due to the level of
evidence in support of their efficacy and their risk-benefit
profile. The cost of other SGAs, which limits their
accessibility for most of the population, adds significant
and unnecessary suffering and impairment for children,
adolescents, and their families. We hope that future
Brazilian guidelines include evidence-based treatment for
these patients.
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